
    
      A multi-centre, randomised, partially blinded, placebo-controlled, three-way crossover,
      incomplete block design study to investigate the, safety, tolerability,
      pharmacodynamics/efficacy and pharmacokinetics of dual bronchodilator therapy with salmeterol
      50 mcg twice daily plus two different doses of GSK233705 (20 and 50 mcg twice daily),
      compared with placebo, salmeterol 50 mcg twice daily alone, and tiotropium 18 mcg once daily
      alone, in subjects with chronic obstructive pulmonary disease
    
  